nodes	percent_of_prediction	percent_of_DWPC	metapath
Lorazepam—UGT2B15—prostate cancer	0.757	1	CbGaD
Lorazepam—UGT2B15—prostate gland—prostate cancer	0.00336	0.25	CbGeAlD
Lorazepam—UGT2B15—urethra—prostate cancer	0.00225	0.167	CbGeAlD
Lorazepam—TSPO—prostate gland—prostate cancer	0.0012	0.0895	CbGeAlD
Lorazepam—GABRB3—prostate gland—prostate cancer	0.00109	0.0812	CbGeAlD
Lorazepam—TSPO—seminal vesicle—prostate cancer	0.00102	0.0757	CbGeAlD
Lorazepam—TSPO—epithelium—prostate cancer	0.000883	0.0657	CbGeAlD
Lorazepam—TSPO—renal system—prostate cancer	0.000819	0.061	CbGeAlD
Lorazepam—TSPO—urethra—prostate cancer	0.000805	0.0599	CbGeAlD
Lorazepam—TSPO—bone marrow—prostate cancer	0.00062	0.0461	CbGeAlD
Lorazepam—TSPO—testis—prostate cancer	0.00053	0.0394	CbGeAlD
Lorazepam—GABRB3—testis—prostate cancer	0.000481	0.0358	CbGeAlD
Lorazepam—Oxazepam—UGT2B15—prostate cancer	0.000406	0.0849	CrCbGaD
Lorazepam—TSPO—lymph node—prostate cancer	0.000384	0.0286	CbGeAlD
Lorazepam—Oxazepam—CYP3A43—prostate cancer	0.000352	0.0736	CrCbGaD
Lorazepam—Clonazepam—NAT2—prostate cancer	0.000338	0.0707	CrCbGaD
Lorazepam—Diclofenac—CYP2C18—prostate cancer	0.000206	0.043	CrCbGaD
Lorazepam—Clotiazepam—CYP2C18—prostate cancer	0.000199	0.0417	CrCbGaD
Lorazepam—Diclofenac—CXCL8—prostate cancer	0.000197	0.0412	CrCbGaD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG5—prostate cancer	0.000145	0.00203	CbGpPWpGaD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG5—prostate cancer	0.000143	0.00199	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—ALPL—prostate cancer	0.000141	0.00197	CbGpPWpGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PLCB2—prostate cancer	0.000138	0.00192	CbGpPWpGaD
Lorazepam—GABRA1—Transmission across Chemical Synapses—RRAS—prostate cancer	0.000136	0.0019	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CSAD—prostate cancer	0.000135	0.00189	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GRHL1—prostate cancer	0.000135	0.00189	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—TST—prostate cancer	0.000135	0.00189	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ADI1—prostate cancer	0.000135	0.00189	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CBR1—prostate cancer	0.000135	0.00189	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PSAT1—prostate cancer	0.000135	0.00189	CbGpPWpGaD
Lorazepam—Tachycardia—Estradiol—prostate cancer	0.000135	0.000878	CcSEcCtD
Lorazepam—Vomiting—Ethinyl Estradiol—prostate cancer	0.000135	0.000877	CcSEcCtD
Lorazepam—Rash—Ethinyl Estradiol—prostate cancer	0.000133	0.00087	CcSEcCtD
Lorazepam—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000133	0.000869	CcSEcCtD
Lorazepam—Alopecia—Etoposide—prostate cancer	0.000133	0.000868	CcSEcCtD
Lorazepam—Headache—Ethinyl Estradiol—prostate cancer	0.000133	0.000864	CcSEcCtD
Lorazepam—Jaundice—Capecitabine—prostate cancer	0.000132	0.000858	CcSEcCtD
Lorazepam—Agranulocytosis—Docetaxel—prostate cancer	0.00013	0.000848	CcSEcCtD
Lorazepam—Blood alkaline phosphatase increased—Doxorubicin—prostate cancer	0.00013	0.000846	CcSEcCtD
Lorazepam—Confusional state—Mitoxantrone—prostate cancer	0.00013	0.000846	CcSEcCtD
Lorazepam—Hypersensitivity—Goserelin—prostate cancer	0.000128	0.000837	CcSEcCtD
Lorazepam—Infection—Mitoxantrone—prostate cancer	0.000128	0.000833	CcSEcCtD
Lorazepam—GABRA1—Orphan transporters—NCOA2—prostate cancer	0.000127	0.00178	CbGpPWpGaD
Lorazepam—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000127	0.000829	CcSEcCtD
Lorazepam—Agranulocytosis—Capecitabine—prostate cancer	0.000126	0.000821	CcSEcCtD
Lorazepam—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000126	0.000821	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—GRHPR—prostate cancer	0.000126	0.00176	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CKMT2—prostate cancer	0.000126	0.00176	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—UGT2B17—prostate cancer	0.000126	0.00176	CbGpPWpGaD
Lorazepam—Nausea—Ethinyl Estradiol—prostate cancer	0.000126	0.000819	CcSEcCtD
Lorazepam—Tachycardia—Mitoxantrone—prostate cancer	0.000126	0.000819	CcSEcCtD
Lorazepam—GABRB3—Orphan transporters—NCOA1—prostate cancer	0.000125	0.00174	CbGpPWpGaD
Lorazepam—Asthenia—Goserelin—prostate cancer	0.000125	0.000815	CcSEcCtD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG5—prostate cancer	0.000125	0.00174	CbGpPWpGaD
Lorazepam—Lethargy—Epirubicin—prostate cancer	0.000125	0.000812	CcSEcCtD
Lorazepam—Erectile dysfunction—Prednisone—prostate cancer	0.000124	0.00081	CcSEcCtD
Lorazepam—Alprazolam—CYP3A5—prostate cancer	0.000124	0.0259	CrCbGaD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKACB—prostate cancer	0.000124	0.00173	CbGpPWpGaD
Lorazepam—Asthenia—Conjugated Estrogens—prostate cancer	0.000124	0.000807	CcSEcCtD
Lorazepam—Bradycardia—Capecitabine—prostate cancer	0.000123	0.000804	CcSEcCtD
Lorazepam—Somnolence—Estradiol—prostate cancer	0.000123	0.0008	CcSEcCtD
Lorazepam—GABRG2—Orphan transporters—NCOA1—prostate cancer	0.000123	0.00171	CbGpPWpGaD
Lorazepam—Hyponatraemia—Epirubicin—prostate cancer	0.000123	0.000799	CcSEcCtD
Lorazepam—Osteoarthritis—Epirubicin—prostate cancer	0.000122	0.000796	CcSEcCtD
Lorazepam—Gastrointestinal haemorrhage—Epirubicin—prostate cancer	0.000122	0.000796	CcSEcCtD
Lorazepam—Diplopia—Epirubicin—prostate cancer	0.000122	0.000796	CcSEcCtD
Lorazepam—GABRB3—Neuronal System—RRAS—prostate cancer	0.000122	0.0017	CbGpPWpGaD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKACB—prostate cancer	0.000122	0.0017	CbGpPWpGaD
Lorazepam—Visual impairment—Docetaxel—prostate cancer	0.000121	0.000786	CcSEcCtD
Lorazepam—GABRB3—Transmission across Chemical Synapses—PLCB2—prostate cancer	0.000121	0.00168	CbGpPWpGaD
Lorazepam—Hypotension—Mitoxantrone—prostate cancer	0.00012	0.000784	CcSEcCtD
Lorazepam—GABRG2—Neuronal System—RRAS—prostate cancer	0.00012	0.00167	CbGpPWpGaD
Lorazepam—Gastrointestinal disorder—Estradiol—prostate cancer	0.000119	0.000777	CcSEcCtD
Lorazepam—Fatigue—Estradiol—prostate cancer	0.000119	0.000776	CcSEcCtD
Lorazepam—GABRB3—Orphan transporters—RXRA—prostate cancer	0.000119	0.00166	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PGAM2—prostate cancer	0.000118	0.00165	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTM3—prostate cancer	0.000118	0.00165	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—RFK—prostate cancer	0.000118	0.00165	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—NAGLU—prostate cancer	0.000118	0.00165	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—MBTPS1—prostate cancer	0.000118	0.00165	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—SULT2B1—prostate cancer	0.000118	0.00165	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—AOX1—prostate cancer	0.000118	0.00165	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—PLCB2—prostate cancer	0.000118	0.00165	CbGpPWpGaD
Lorazepam—Pain—Estradiol—prostate cancer	0.000118	0.00077	CcSEcCtD
Lorazepam—Constipation—Estradiol—prostate cancer	0.000118	0.00077	CcSEcCtD
Lorazepam—Vertigo—Etoposide—prostate cancer	0.000118	0.000768	CcSEcCtD
Lorazepam—Visual impairment—Capecitabine—prostate cancer	0.000117	0.000761	CcSEcCtD
Lorazepam—GABRG2—Orphan transporters—RXRA—prostate cancer	0.000117	0.00163	CbGpPWpGaD
Lorazepam—Cardiac arrest—Epirubicin—prostate cancer	0.000116	0.000757	CcSEcCtD
Lorazepam—Lethargy—Doxorubicin—prostate cancer	0.000115	0.000751	CcSEcCtD
Lorazepam—Dizziness—Goserelin—prostate cancer	0.000115	0.000751	CcSEcCtD
Lorazepam—GABRB3—Transmission across Chemical Synapses—SLC22A1—prostate cancer	0.000115	0.0016	CbGpPWpGaD
Lorazepam—Ataxia—Epirubicin—prostate cancer	0.000115	0.000748	CcSEcCtD
Lorazepam—Somnolence—Mitoxantrone—prostate cancer	0.000114	0.000746	CcSEcCtD
Lorazepam—Dizziness—Conjugated Estrogens—prostate cancer	0.000114	0.000744	CcSEcCtD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000114	0.00159	CbGpPWpGaD
Lorazepam—Feeling abnormal—Estradiol—prostate cancer	0.000114	0.000742	CcSEcCtD
Lorazepam—Convulsion—Etoposide—prostate cancer	0.000114	0.000741	CcSEcCtD
Lorazepam—Hyponatraemia—Doxorubicin—prostate cancer	0.000113	0.000739	CcSEcCtD
Lorazepam—Hypertension—Etoposide—prostate cancer	0.000113	0.000738	CcSEcCtD
Lorazepam—Osteoarthritis—Doxorubicin—prostate cancer	0.000113	0.000736	CcSEcCtD
Lorazepam—Gastrointestinal haemorrhage—Doxorubicin—prostate cancer	0.000113	0.000736	CcSEcCtD
Lorazepam—Diplopia—Doxorubicin—prostate cancer	0.000113	0.000736	CcSEcCtD
Lorazepam—GABRG2—Transmission across Chemical Synapses—SLC22A1—prostate cancer	0.000113	0.00158	CbGpPWpGaD
Lorazepam—Liver function test abnormal—Epirubicin—prostate cancer	0.000113	0.000735	CcSEcCtD
Lorazepam—Chills—Docetaxel—prostate cancer	0.000112	0.000732	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—AMACR—prostate cancer	0.000112	0.00157	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP3A43—prostate cancer	0.000112	0.00157	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—NAT1—prostate cancer	0.000112	0.00157	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—SRD5A2—prostate cancer	0.000112	0.00157	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—DEGS1—prostate cancer	0.000112	0.00157	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000112	0.00156	CbGpPWpGaD
Lorazepam—Arrhythmia—Docetaxel—prostate cancer	0.000112	0.000729	CcSEcCtD
Lorazepam—Fatigue—Mitoxantrone—prostate cancer	0.000111	0.000723	CcSEcCtD
Lorazepam—Vomiting—Goserelin—prostate cancer	0.000111	0.000722	CcSEcCtD
Lorazepam—Alopecia—Docetaxel—prostate cancer	0.000111	0.000721	CcSEcCtD
Lorazepam—Pain—Mitoxantrone—prostate cancer	0.00011	0.000717	CcSEcCtD
Lorazepam—Constipation—Mitoxantrone—prostate cancer	0.00011	0.000717	CcSEcCtD
Lorazepam—Diazepam—CYP2C18—prostate cancer	0.00011	0.023	CrCbGaD
Lorazepam—Bradycardia—Prednisone—prostate cancer	0.00011	0.000716	CcSEcCtD
Lorazepam—Rash—Goserelin—prostate cancer	0.00011	0.000716	CcSEcCtD
Lorazepam—Dermatitis—Goserelin—prostate cancer	0.00011	0.000715	CcSEcCtD
Lorazepam—Vomiting—Conjugated Estrogens—prostate cancer	0.00011	0.000715	CcSEcCtD
Lorazepam—GABRB3—Transmission across Chemical Synapses—GNG5—prostate cancer	0.000109	0.00153	CbGpPWpGaD
Lorazepam—Headache—Goserelin—prostate cancer	0.000109	0.000711	CcSEcCtD
Lorazepam—Erythema—Docetaxel—prostate cancer	0.000109	0.00071	CcSEcCtD
Lorazepam—Rash—Conjugated Estrogens—prostate cancer	0.000109	0.000709	CcSEcCtD
Lorazepam—Chills—Capecitabine—prostate cancer	0.000109	0.000709	CcSEcCtD
Lorazepam—Dermatitis—Conjugated Estrogens—prostate cancer	0.000109	0.000708	CcSEcCtD
Lorazepam—Arrhythmia—Capecitabine—prostate cancer	0.000108	0.000706	CcSEcCtD
Lorazepam—Headache—Conjugated Estrogens—prostate cancer	0.000108	0.000705	CcSEcCtD
Lorazepam—Confusional state—Etoposide—prostate cancer	0.000108	0.000703	CcSEcCtD
Lorazepam—Hallucination—Prednisone—prostate cancer	0.000107	0.0007	CcSEcCtD
Lorazepam—Cardiac arrest—Doxorubicin—prostate cancer	0.000107	0.0007	CcSEcCtD
Lorazepam—GABRG2—Transmission across Chemical Synapses—GNG5—prostate cancer	0.000107	0.0015	CbGpPWpGaD
Lorazepam—GABRA1—Orphan transporters—NCOA1—prostate cancer	0.000107	0.0015	CbGpPWpGaD
Lorazepam—Alopecia—Capecitabine—prostate cancer	0.000107	0.000698	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—HSD17B1—prostate cancer	0.000107	0.00149	CbGpPWpGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKACB—prostate cancer	0.000106	0.00149	CbGpPWpGaD
Lorazepam—Infection—Etoposide—prostate cancer	0.000106	0.000693	CcSEcCtD
Lorazepam—Ataxia—Doxorubicin—prostate cancer	0.000106	0.000692	CcSEcCtD
Lorazepam—Feeling abnormal—Mitoxantrone—prostate cancer	0.000106	0.000691	CcSEcCtD
Lorazepam—Erythema—Capecitabine—prostate cancer	0.000106	0.000688	CcSEcCtD
Lorazepam—Thrombocytopenia—Etoposide—prostate cancer	0.000105	0.000683	CcSEcCtD
Lorazepam—Midazolam—SLC22A1—prostate cancer	0.000105	0.0219	CrCbGaD
Lorazepam—GABRA1—Neuronal System—RRAS—prostate cancer	0.000105	0.00146	CbGpPWpGaD
Lorazepam—Tachycardia—Etoposide—prostate cancer	0.000104	0.000681	CcSEcCtD
Lorazepam—Liver function test abnormal—Doxorubicin—prostate cancer	0.000104	0.00068	CcSEcCtD
Lorazepam—Bromazepam—CYP2E1—prostate cancer	0.000104	0.0217	CrCbGaD
Lorazepam—Nausea—Goserelin—prostate cancer	0.000103	0.000674	CcSEcCtD
Lorazepam—GABRA1—Transmission across Chemical Synapses—PLCB2—prostate cancer	0.000103	0.00144	CbGpPWpGaD
Lorazepam—Bromazepam—CYP2C19—prostate cancer	0.000103	0.0215	CrCbGaD
Lorazepam—Nausea—Conjugated Estrogens—prostate cancer	0.000102	0.000668	CcSEcCtD
Lorazepam—GABRA1—Orphan transporters—RXRA—prostate cancer	0.000102	0.00142	CbGpPWpGaD
Lorazepam—Hypersensitivity—Estradiol—prostate cancer	0.000102	0.000663	CcSEcCtD
Lorazepam—Pancytopenia—Epirubicin—prostate cancer	0.0001	0.000653	CcSEcCtD
Lorazepam—Hypotension—Etoposide—prostate cancer	0.0001	0.000652	CcSEcCtD
Lorazepam—Vision blurred—Capecitabine—prostate cancer	9.94e-05	0.000648	CcSEcCtD
Lorazepam—Asthenia—Estradiol—prostate cancer	9.91e-05	0.000646	CcSEcCtD
Lorazepam—Tremor—Capecitabine—prostate cancer	9.89e-05	0.000644	CcSEcCtD
Lorazepam—GABRA1—Transmission across Chemical Synapses—SLC22A1—prostate cancer	9.87e-05	0.00138	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC7A1—prostate cancer	9.79e-05	0.00137	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—EGR1—prostate cancer	9.78e-05	0.00136	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—PRKACB—prostate cancer	9.76e-05	0.00136	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—ACHE—prostate cancer	9.75e-05	0.00136	CbGpPWpGaD
Lorazepam—Clonazepam—CYP2E1—prostate cancer	9.72e-05	0.0203	CrCbGaD
Lorazepam—GABRB3—BDNF signaling pathway—NGFR—prostate cancer	9.72e-05	0.00136	CbGpPWpGaD
Lorazepam—Arrhythmia—Prednisone—prostate cancer	9.65e-05	0.000629	CcSEcCtD
Lorazepam—GABRG2—Transmission across Chemical Synapses—ACHE—prostate cancer	9.57e-05	0.00134	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—HPGD—prostate cancer	9.54e-05	0.00133	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—B4GALT4—prostate cancer	9.54e-05	0.00133	CbGpPWpGaD
Lorazepam—Alopecia—Prednisone—prostate cancer	9.54e-05	0.000622	CcSEcCtD
Lorazepam—Somnolence—Etoposide—prostate cancer	9.52e-05	0.00062	CcSEcCtD
Lorazepam—Vertigo—Capecitabine—prostate cancer	9.48e-05	0.000618	CcSEcCtD
Lorazepam—Hypersensitivity—Mitoxantrone—prostate cancer	9.48e-05	0.000618	CcSEcCtD
Lorazepam—Convulsion—Docetaxel—prostate cancer	9.44e-05	0.000615	CcSEcCtD
Lorazepam—Hypertension—Docetaxel—prostate cancer	9.41e-05	0.000613	CcSEcCtD
Lorazepam—Drowsiness—Epirubicin—prostate cancer	9.41e-05	0.000613	CcSEcCtD
Lorazepam—Erythema—Prednisone—prostate cancer	9.4e-05	0.000613	CcSEcCtD
Lorazepam—GABRA1—Transmission across Chemical Synapses—GNG5—prostate cancer	9.39e-05	0.00131	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—PRKACB—prostate cancer	9.32e-05	0.0013	CbGpPWpGaD
Lorazepam—Diclofenac—CYP2E1—prostate cancer	9.32e-05	0.0195	CrCbGaD
Lorazepam—Pancytopenia—Doxorubicin—prostate cancer	9.27e-05	0.000604	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Etoposide—prostate cancer	9.24e-05	0.000602	CcSEcCtD
Lorazepam—GABRB3—Neuronal System—PLCB2—prostate cancer	9.23e-05	0.00129	CbGpPWpGaD
Lorazepam—Asthenia—Mitoxantrone—prostate cancer	9.23e-05	0.000602	CcSEcCtD
Lorazepam—Diclofenac—CYP2C19—prostate cancer	9.23e-05	0.0193	CrCbGaD
Lorazepam—Fatigue—Etoposide—prostate cancer	9.23e-05	0.000601	CcSEcCtD
Lorazepam—Diclofenac—CYP1A1—prostate cancer	9.2e-05	0.0192	CrCbGaD
Lorazepam—Jaundice—Epirubicin—prostate cancer	9.17e-05	0.000598	CcSEcCtD
Lorazepam—GABRG2—Transmission across Chemical Synapses—PRKACB—prostate cancer	9.15e-05	0.00128	CbGpPWpGaD
Lorazepam—Constipation—Etoposide—prostate cancer	9.15e-05	0.000597	CcSEcCtD
Lorazepam—Pain—Etoposide—prostate cancer	9.15e-05	0.000597	CcSEcCtD
Lorazepam—Dizziness—Estradiol—prostate cancer	9.13e-05	0.000595	CcSEcCtD
Lorazepam—Hypertension—Capecitabine—prostate cancer	9.11e-05	0.000594	CcSEcCtD
Lorazepam—Triazolam—CYP3A5—prostate cancer	9.1e-05	0.019	CrCbGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL1RN—prostate cancer	9.08e-05	0.00127	CbGpPWpGaD
Lorazepam—GABRB3—Orphan transporters—PPARA—prostate cancer	9.08e-05	0.00127	CbGpPWpGaD
Lorazepam—Dry mouth—Docetaxel—prostate cancer	9.07e-05	0.000591	CcSEcCtD
Lorazepam—GABRG2—Neuronal System—PLCB2—prostate cancer	9.07e-05	0.00127	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC39A1—prostate cancer	9.02e-05	0.00126	CbGpPWpGaD
Lorazepam—Clozapine—CYP1B1—prostate cancer	8.98e-05	0.0188	CrCbGaD
Lorazepam—UGT2B15—Metabolism—TNFRSF21—prostate cancer	8.97e-05	0.00125	CbGpPWpGaD
Lorazepam—Confusional state—Docetaxel—prostate cancer	8.97e-05	0.000585	CcSEcCtD
Lorazepam—Clotiazepam—CYP2C19—prostate cancer	8.94e-05	0.0187	CrCbGaD
Lorazepam—GABRG2—Orphan transporters—PPARA—prostate cancer	8.92e-05	0.00124	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—VAV3—prostate cancer	8.91e-05	0.00124	CbGpPWpGaD
Lorazepam—Vision blurred—Prednisone—prostate cancer	8.86e-05	0.000577	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC39A1—prostate cancer	8.85e-05	0.00124	CbGpPWpGaD
Lorazepam—Infection—Docetaxel—prostate cancer	8.84e-05	0.000576	CcSEcCtD
Lorazepam—Oxazepam—CYP3A5—prostate cancer	8.83e-05	0.0185	CrCbGaD
Lorazepam—Flurazepam—CYP2A6—prostate cancer	8.82e-05	0.0184	CrCbGaD
Lorazepam—Feeling abnormal—Etoposide—prostate cancer	8.82e-05	0.000575	CcSEcCtD
Lorazepam—GABRB3—Neuronal System—SLC22A1—prostate cancer	8.81e-05	0.00123	CbGpPWpGaD
Lorazepam—Dry mouth—Capecitabine—prostate cancer	8.79e-05	0.000573	CcSEcCtD
Lorazepam—Vomiting—Estradiol—prostate cancer	8.78e-05	0.000572	CcSEcCtD
Lorazepam—Agranulocytosis—Epirubicin—prostate cancer	8.78e-05	0.000572	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—MTAP—prostate cancer	8.73e-05	0.00122	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP7B1—prostate cancer	8.73e-05	0.00122	CbGpPWpGaD
Lorazepam—Thrombocytopenia—Docetaxel—prostate cancer	8.71e-05	0.000568	CcSEcCtD
Lorazepam—Rash—Estradiol—prostate cancer	8.71e-05	0.000568	CcSEcCtD
Lorazepam—Drowsiness—Doxorubicin—prostate cancer	8.7e-05	0.000567	CcSEcCtD
Lorazepam—Dermatitis—Estradiol—prostate cancer	8.7e-05	0.000567	CcSEcCtD
Lorazepam—Confusional state—Capecitabine—prostate cancer	8.68e-05	0.000566	CcSEcCtD
Lorazepam—Tachycardia—Docetaxel—prostate cancer	8.68e-05	0.000566	CcSEcCtD
Lorazepam—Headache—Estradiol—prostate cancer	8.65e-05	0.000564	CcSEcCtD
Lorazepam—GABRG2—Neuronal System—SLC22A1—prostate cancer	8.65e-05	0.00121	CbGpPWpGaD
Lorazepam—Agitation—Prednisone—prostate cancer	8.64e-05	0.000563	CcSEcCtD
Lorazepam—Bradycardia—Epirubicin—prostate cancer	8.6e-05	0.00056	CcSEcCtD
Lorazepam—Infection—Capecitabine—prostate cancer	8.56e-05	0.000558	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—SULT1E1—prostate cancer	8.51e-05	0.00119	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—SRD5A1—prostate cancer	8.51e-05	0.00119	CbGpPWpGaD
Lorazepam—Jaundice—Doxorubicin—prostate cancer	8.48e-05	0.000553	CcSEcCtD
Lorazepam—Midazolam—CYP3A5—prostate cancer	8.45e-05	0.0177	CrCbGaD
Lorazepam—Vertigo—Prednisone—prostate cancer	8.44e-05	0.00055	CcSEcCtD
Lorazepam—Thrombocytopenia—Capecitabine—prostate cancer	8.43e-05	0.00055	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—ESR2—prostate cancer	8.42e-05	0.00117	CbGpPWpGaD
Lorazepam—Tachycardia—Capecitabine—prostate cancer	8.41e-05	0.000548	CcSEcCtD
Lorazepam—GABRB3—Neuronal System—GNG5—prostate cancer	8.38e-05	0.00117	CbGpPWpGaD
Lorazepam—GABRA1—Transmission across Chemical Synapses—ACHE—prostate cancer	8.37e-05	0.00117	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—TH—prostate cancer	8.36e-05	0.00117	CbGpPWpGaD
Lorazepam—Hypotension—Docetaxel—prostate cancer	8.31e-05	0.000542	CcSEcCtD
Lorazepam—GABRG2—Neuronal System—GNG5—prostate cancer	8.23e-05	0.00115	CbGpPWpGaD
Lorazepam—Nausea—Estradiol—prostate cancer	8.2e-05	0.000535	CcSEcCtD
Lorazepam—Quazepam—CYP2C19—prostate cancer	8.19e-05	0.0171	CrCbGaD
Lorazepam—Vomiting—Mitoxantrone—prostate cancer	8.18e-05	0.000533	CcSEcCtD
Lorazepam—Convulsion—Prednisone—prostate cancer	8.14e-05	0.000531	CcSEcCtD
Lorazepam—Visual impairment—Epirubicin—prostate cancer	8.14e-05	0.00053	CcSEcCtD
Lorazepam—Agranulocytosis—Doxorubicin—prostate cancer	8.12e-05	0.000529	CcSEcCtD
Lorazepam—Hypertension—Prednisone—prostate cancer	8.12e-05	0.000529	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—ACSL4—prostate cancer	8.11e-05	0.00113	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—HSD17B3—prostate cancer	8.11e-05	0.00113	CbGpPWpGaD
Lorazepam—Rash—Mitoxantrone—prostate cancer	8.11e-05	0.000529	CcSEcCtD
Lorazepam—Dermatitis—Mitoxantrone—prostate cancer	8.11e-05	0.000528	CcSEcCtD
Lorazepam—Headache—Mitoxantrone—prostate cancer	8.06e-05	0.000525	CcSEcCtD
Lorazepam—Hypotension—Capecitabine—prostate cancer	8.05e-05	0.000525	CcSEcCtD
Lorazepam—GABRA1—Transmission across Chemical Synapses—PRKACB—prostate cancer	8e-05	0.00112	CbGpPWpGaD
Lorazepam—Bradycardia—Doxorubicin—prostate cancer	7.95e-05	0.000518	CcSEcCtD
Lorazepam—GABRA1—Neuronal System—PLCB2—prostate cancer	7.93e-05	0.00111	CbGpPWpGaD
Lorazepam—Somnolence—Docetaxel—prostate cancer	7.91e-05	0.000515	CcSEcCtD
Lorazepam—Hypersensitivity—Etoposide—prostate cancer	7.89e-05	0.000514	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—EGR1—prostate cancer	7.87e-05	0.0011	CbGpPWpGaD
Lorazepam—GABRA1—Orphan transporters—PPARA—prostate cancer	7.8e-05	0.00109	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ARG2—prostate cancer	7.78e-05	0.00109	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PHGDH—prostate cancer	7.78e-05	0.00109	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—UMPS—prostate cancer	7.78e-05	0.00109	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC39A1—prostate cancer	7.74e-05	0.00108	CbGpPWpGaD
Lorazepam—Gastrointestinal disorder—Docetaxel—prostate cancer	7.68e-05	0.000501	CcSEcCtD
Lorazepam—Asthenia—Etoposide—prostate cancer	7.68e-05	0.000501	CcSEcCtD
Lorazepam—Fatigue—Docetaxel—prostate cancer	7.67e-05	0.0005	CcSEcCtD
Lorazepam—Nausea—Mitoxantrone—prostate cancer	7.64e-05	0.000498	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—LDHB—prostate cancer	7.63e-05	0.00106	CbGpPWpGaD
Lorazepam—Infection—Prednisone—prostate cancer	7.62e-05	0.000497	CcSEcCtD
Lorazepam—Constipation—Docetaxel—prostate cancer	7.61e-05	0.000496	CcSEcCtD
Lorazepam—Pain—Docetaxel—prostate cancer	7.61e-05	0.000496	CcSEcCtD
Lorazepam—Chills—Epirubicin—prostate cancer	7.58e-05	0.000494	CcSEcCtD
Lorazepam—GABRA1—Neuronal System—SLC22A1—prostate cancer	7.56e-05	0.00105	CbGpPWpGaD
Lorazepam—Arrhythmia—Epirubicin—prostate cancer	7.54e-05	0.000492	CcSEcCtD
Lorazepam—Visual impairment—Doxorubicin—prostate cancer	7.53e-05	0.000491	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—GJA1—prostate cancer	7.5e-05	0.00105	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP3A5—prostate cancer	7.49e-05	0.00104	CbGpPWpGaD
Lorazepam—Tachycardia—Prednisone—prostate cancer	7.49e-05	0.000488	CcSEcCtD
Lorazepam—GABRB3—Neuronal System—ACHE—prostate cancer	7.47e-05	0.00104	CbGpPWpGaD
Lorazepam—Alopecia—Epirubicin—prostate cancer	7.46e-05	0.000486	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—AR—prostate cancer	7.44e-05	0.00104	CbGpPWpGaD
Lorazepam—Gastrointestinal disorder—Capecitabine—prostate cancer	7.44e-05	0.000485	CcSEcCtD
Lorazepam—Fatigue—Capecitabine—prostate cancer	7.42e-05	0.000484	CcSEcCtD
Lorazepam—Constipation—Capecitabine—prostate cancer	7.36e-05	0.00048	CcSEcCtD
Lorazepam—Pain—Capecitabine—prostate cancer	7.36e-05	0.00048	CcSEcCtD
Lorazepam—Erythema—Epirubicin—prostate cancer	7.35e-05	0.000479	CcSEcCtD
Lorazepam—GABRB3—Transmembrane transport of small molecules—CYP7B1—prostate cancer	7.35e-05	0.00103	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—ACHE—prostate cancer	7.33e-05	0.00102	CbGpPWpGaD
Lorazepam—Feeling abnormal—Docetaxel—prostate cancer	7.33e-05	0.000478	CcSEcCtD
Lorazepam—Diazepam—CYP3A5—prostate cancer	7.24e-05	0.0151	CrCbGaD
Lorazepam—UGT2B15—Metabolism—PDHA1—prostate cancer	7.23e-05	0.00101	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—TCN2—prostate cancer	7.23e-05	0.00101	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—UCP3—prostate cancer	7.23e-05	0.00101	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTA3—prostate cancer	7.23e-05	0.00101	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—CYP7B1—prostate cancer	7.22e-05	0.00101	CbGpPWpGaD
Lorazepam—Tension—Epirubicin—prostate cancer	7.21e-05	0.00047	CcSEcCtD
Lorazepam—GABRB3—Orphan transporters—CREBBP—prostate cancer	7.21e-05	0.00101	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—GNG5—prostate cancer	7.19e-05	0.001	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC26A4—prostate cancer	7.16e-05	0.000999	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC12A2—prostate cancer	7.16e-05	0.000999	CbGpPWpGaD
Lorazepam—GABRB3—Neuronal System—PRKACB—prostate cancer	7.14e-05	0.000997	CbGpPWpGaD
Lorazepam—Nervousness—Epirubicin—prostate cancer	7.14e-05	0.000465	CcSEcCtD
Lorazepam—Feeling abnormal—Capecitabine—prostate cancer	7.1e-05	0.000463	CcSEcCtD
Lorazepam—GABRG2—Orphan transporters—CREBBP—prostate cancer	7.08e-05	0.000988	CbGpPWpGaD
Lorazepam—Dizziness—Etoposide—prostate cancer	7.08e-05	0.000461	CcSEcCtD
Lorazepam—Nitrazepam—CYP2E1—prostate cancer	7.05e-05	0.0147	CrCbGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC12A2—prostate cancer	7.03e-05	0.000981	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC26A4—prostate cancer	7.03e-05	0.000981	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—PRKACB—prostate cancer	7.01e-05	0.000979	CbGpPWpGaD
Lorazepam—Chills—Doxorubicin—prostate cancer	7.01e-05	0.000457	CcSEcCtD
Lorazepam—Arrhythmia—Doxorubicin—prostate cancer	6.98e-05	0.000455	CcSEcCtD
Lorazepam—Vision blurred—Epirubicin—prostate cancer	6.93e-05	0.000452	CcSEcCtD
Lorazepam—Clozapine—CYP2A6—prostate cancer	6.92e-05	0.0145	CrCbGaD
Lorazepam—Alopecia—Doxorubicin—prostate cancer	6.9e-05	0.00045	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—HSD3B1—prostate cancer	6.9e-05	0.000963	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—SLC22A3—prostate cancer	6.9e-05	0.000963	CbGpPWpGaD
Lorazepam—Vomiting—Etoposide—prostate cancer	6.81e-05	0.000444	CcSEcCtD
Lorazepam—Erythema—Doxorubicin—prostate cancer	6.8e-05	0.000443	CcSEcCtD
Lorazepam—GABRB3—Transmission across Chemical Synapses—COMT—prostate cancer	6.79e-05	0.000947	CbGpPWpGaD
Lorazepam—Agitation—Epirubicin—prostate cancer	6.76e-05	0.00044	CcSEcCtD
Lorazepam—Rash—Etoposide—prostate cancer	6.75e-05	0.00044	CcSEcCtD
Lorazepam—Dermatitis—Etoposide—prostate cancer	6.74e-05	0.000439	CcSEcCtD
Lorazepam—Headache—Etoposide—prostate cancer	6.71e-05	0.000437	CcSEcCtD
Lorazepam—Tension—Doxorubicin—prostate cancer	6.67e-05	0.000435	CcSEcCtD
Lorazepam—GABRG2—Transmission across Chemical Synapses—COMT—prostate cancer	6.67e-05	0.00093	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTA4—prostate cancer	6.61e-05	0.000923	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—TBXAS1—prostate cancer	6.61e-05	0.000923	CbGpPWpGaD
Lorazepam—Fatigue—Prednisone—prostate cancer	6.61e-05	0.000431	CcSEcCtD
Lorazepam—Nervousness—Doxorubicin—prostate cancer	6.61e-05	0.000431	CcSEcCtD
Lorazepam—Vertigo—Epirubicin—prostate cancer	6.6e-05	0.00043	CcSEcCtD
Lorazepam—Constipation—Prednisone—prostate cancer	6.56e-05	0.000428	CcSEcCtD
Lorazepam—Hypersensitivity—Docetaxel—prostate cancer	6.55e-05	0.000427	CcSEcCtD
Lorazepam—Bromazepam—CYP3A4—prostate cancer	6.53e-05	0.0136	CrCbGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL10—prostate cancer	6.5e-05	0.000907	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTA2—prostate cancer	6.45e-05	0.000899	CbGpPWpGaD
Lorazepam—Vision blurred—Doxorubicin—prostate cancer	6.41e-05	0.000418	CcSEcCtD
Lorazepam—GABRA1—Neuronal System—ACHE—prostate cancer	6.41e-05	0.000894	CbGpPWpGaD
Lorazepam—Asthenia—Docetaxel—prostate cancer	6.38e-05	0.000416	CcSEcCtD
Lorazepam—Convulsion—Epirubicin—prostate cancer	6.37e-05	0.000415	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—SULT1A1—prostate cancer	6.37e-05	0.000888	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ABCG5—prostate cancer	6.37e-05	0.000888	CbGpPWpGaD
Lorazepam—Nausea—Etoposide—prostate cancer	6.36e-05	0.000414	CcSEcCtD
Lorazepam—Hypertension—Epirubicin—prostate cancer	6.35e-05	0.000414	CcSEcCtD
Lorazepam—Hypersensitivity—Capecitabine—prostate cancer	6.35e-05	0.000414	CcSEcCtD
Lorazepam—Chlordiazepoxide—CYP3A4—prostate cancer	6.34e-05	0.0133	CrCbGaD
Lorazepam—Feeling abnormal—Prednisone—prostate cancer	6.32e-05	0.000412	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—CYP7B1—prostate cancer	6.31e-05	0.00088	CbGpPWpGaD
Lorazepam—Flurazepam—CYP2E1—prostate cancer	6.27e-05	0.0131	CrCbGaD
Lorazepam—Agitation—Doxorubicin—prostate cancer	6.25e-05	0.000407	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—GSTA1—prostate cancer	6.22e-05	0.000868	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—BAD—prostate cancer	6.19e-05	0.000864	CbGpPWpGaD
Lorazepam—GABRA1—Orphan transporters—CREBBP—prostate cancer	6.19e-05	0.000864	CbGpPWpGaD
Lorazepam—Asthenia—Capecitabine—prostate cancer	6.18e-05	0.000403	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—GSTO1—prostate cancer	6.15e-05	0.000858	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—HSD3B2—prostate cancer	6.15e-05	0.000858	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—NAT2—prostate cancer	6.15e-05	0.000858	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC26A4—prostate cancer	6.15e-05	0.000858	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC12A2—prostate cancer	6.15e-05	0.000858	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—PRKACB—prostate cancer	6.13e-05	0.000855	CbGpPWpGaD
Lorazepam—Clonazepam—CYP3A4—prostate cancer	6.12e-05	0.0128	CrCbGaD
Lorazepam—Dry mouth—Epirubicin—prostate cancer	6.12e-05	0.000399	CcSEcCtD
Lorazepam—Vertigo—Doxorubicin—prostate cancer	6.11e-05	0.000398	CcSEcCtD
Lorazepam—Confusional state—Epirubicin—prostate cancer	6.05e-05	0.000394	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—NR3C1—prostate cancer	6.01e-05	0.000839	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—APC—prostate cancer	6e-05	0.000837	CbGpPWpGaD
Lorazepam—Infection—Epirubicin—prostate cancer	5.96e-05	0.000388	CcSEcCtD
Lorazepam—Temazepam—CYP2C19—prostate cancer	5.93e-05	0.0124	CrCbGaD
Lorazepam—Clorazepate—CYP3A4—prostate cancer	5.93e-05	0.0124	CrCbGaD
Lorazepam—GABRB3—BDNF signaling pathway—IRS1—prostate cancer	5.93e-05	0.000827	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PLCB2—prostate cancer	5.9e-05	0.000823	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP2C18—prostate cancer	5.9e-05	0.000823	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—LRP2—prostate cancer	5.9e-05	0.000823	CbGpPWpGaD
Lorazepam—Convulsion—Doxorubicin—prostate cancer	5.89e-05	0.000384	CcSEcCtD
Lorazepam—Dizziness—Docetaxel—prostate cancer	5.88e-05	0.000383	CcSEcCtD
Lorazepam—Thrombocytopenia—Epirubicin—prostate cancer	5.87e-05	0.000383	CcSEcCtD
Lorazepam—Hypertension—Doxorubicin—prostate cancer	5.87e-05	0.000383	CcSEcCtD
Lorazepam—Diclofenac—CYP3A4—prostate cancer	5.87e-05	0.0123	CrCbGaD
Lorazepam—Tachycardia—Epirubicin—prostate cancer	5.86e-05	0.000382	CcSEcCtD
Lorazepam—GABRA1—Transmission across Chemical Synapses—COMT—prostate cancer	5.83e-05	0.000813	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC22A3—prostate cancer	5.81e-05	0.000811	CbGpPWpGaD
Lorazepam—Midazolam—CYP2E1—prostate cancer	5.81e-05	0.0121	CrCbGaD
Lorazepam—UGT2B15—Metabolism—P4HB—prostate cancer	5.78e-05	0.000807	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—GSK3B—prostate cancer	5.75e-05	0.000803	CbGpPWpGaD
Lorazepam—Diclofenac—PTGS2—prostate cancer	5.75e-05	0.012	CrCbGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	5.7e-05	0.000796	CbGpPWpGaD
Lorazepam—Dizziness—Capecitabine—prostate cancer	5.7e-05	0.000371	CcSEcCtD
Lorazepam—Clotiazepam—CYP3A4—prostate cancer	5.69e-05	0.0119	CrCbGaD
Lorazepam—Dry mouth—Doxorubicin—prostate cancer	5.66e-05	0.000369	CcSEcCtD
Lorazepam—Vomiting—Docetaxel—prostate cancer	5.66e-05	0.000369	CcSEcCtD
Lorazepam—Hypersensitivity—Prednisone—prostate cancer	5.65e-05	0.000368	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—SLC22A1—prostate cancer	5.62e-05	0.000785	CbGpPWpGaD
Lorazepam—Rash—Docetaxel—prostate cancer	5.61e-05	0.000366	CcSEcCtD
Lorazepam—Hypotension—Epirubicin—prostate cancer	5.61e-05	0.000365	CcSEcCtD
Lorazepam—Dermatitis—Docetaxel—prostate cancer	5.6e-05	0.000365	CcSEcCtD
Lorazepam—Confusional state—Doxorubicin—prostate cancer	5.6e-05	0.000365	CcSEcCtD
Lorazepam—Headache—Docetaxel—prostate cancer	5.57e-05	0.000363	CcSEcCtD
Lorazepam—Infection—Doxorubicin—prostate cancer	5.52e-05	0.000359	CcSEcCtD
Lorazepam—Asthenia—Prednisone—prostate cancer	5.5e-05	0.000359	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—SULT2A1—prostate cancer	5.48e-05	0.000765	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—HIF1A—prostate cancer	5.48e-05	0.000764	CbGpPWpGaD
Lorazepam—Vomiting—Capecitabine—prostate cancer	5.48e-05	0.000357	CcSEcCtD
Lorazepam—Thrombocytopenia—Doxorubicin—prostate cancer	5.44e-05	0.000354	CcSEcCtD
Lorazepam—Rash—Capecitabine—prostate cancer	5.43e-05	0.000354	CcSEcCtD
Lorazepam—Dermatitis—Capecitabine—prostate cancer	5.43e-05	0.000354	CcSEcCtD
Lorazepam—Tachycardia—Doxorubicin—prostate cancer	5.42e-05	0.000353	CcSEcCtD
Lorazepam—Headache—Capecitabine—prostate cancer	5.4e-05	0.000352	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—MED12—prostate cancer	5.39e-05	0.000752	CbGpPWpGaD
Lorazepam—Alprazolam—CYP3A4—prostate cancer	5.37e-05	0.0112	CrCbGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ABCG5—prostate cancer	5.36e-05	0.000748	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GNG5—prostate cancer	5.35e-05	0.000746	CbGpPWpGaD
Lorazepam—Somnolence—Epirubicin—prostate cancer	5.33e-05	0.000348	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—MAP2K1—prostate cancer	5.31e-05	0.00074	CbGpPWpGaD
Lorazepam—Nausea—Docetaxel—prostate cancer	5.28e-05	0.000344	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ABCG5—prostate cancer	5.26e-05	0.000735	CbGpPWpGaD
Lorazepam—Quazepam—CYP3A4—prostate cancer	5.21e-05	0.0109	CrCbGaD
Lorazepam—GABRB3—Neuronal System—COMT—prostate cancer	5.2e-05	0.000726	CbGpPWpGaD
Lorazepam—Hypotension—Doxorubicin—prostate cancer	5.19e-05	0.000338	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Epirubicin—prostate cancer	5.18e-05	0.000338	CcSEcCtD
Lorazepam—Fatigue—Epirubicin—prostate cancer	5.17e-05	0.000337	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—NCOA3—prostate cancer	5.15e-05	0.000719	CbGpPWpGaD
Lorazepam—Constipation—Epirubicin—prostate cancer	5.13e-05	0.000334	CcSEcCtD
Lorazepam—Pain—Epirubicin—prostate cancer	5.13e-05	0.000334	CcSEcCtD
Lorazepam—Nausea—Capecitabine—prostate cancer	5.12e-05	0.000333	CcSEcCtD
Lorazepam—GABRG2—Neuronal System—COMT—prostate cancer	5.11e-05	0.000713	CbGpPWpGaD
Lorazepam—Dizziness—Prednisone—prostate cancer	5.07e-05	0.000331	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC22A3—prostate cancer	4.99e-05	0.000696	CbGpPWpGaD
Lorazepam—Diazepam—CYP2E1—prostate cancer	4.98e-05	0.0104	CrCbGaD
Lorazepam—Feeling abnormal—Epirubicin—prostate cancer	4.94e-05	0.000322	CcSEcCtD
Lorazepam—Somnolence—Doxorubicin—prostate cancer	4.94e-05	0.000322	CcSEcCtD
Lorazepam—Diazepam—CYP2C19—prostate cancer	4.93e-05	0.0103	CrCbGaD
Lorazepam—UGT2B15—Metabolism—HPGDS—prostate cancer	4.92e-05	0.000686	CbGpPWpGaD
Lorazepam—Clozapine—CYP2E1—prostate cancer	4.91e-05	0.0103	CrCbGaD
Lorazepam—UGT2B15—Metabolism—CYP2C19—prostate cancer	4.89e-05	0.000682	CbGpPWpGaD
Lorazepam—Vomiting—Prednisone—prostate cancer	4.88e-05	0.000318	CcSEcCtD
Lorazepam—Clozapine—CYP2C19—prostate cancer	4.87e-05	0.0102	CrCbGaD
Lorazepam—Clozapine—CYP1A1—prostate cancer	4.85e-05	0.0101	CrCbGaD
Lorazepam—GABRB3—BDNF signaling pathway—JAK2—prostate cancer	4.84e-05	0.000675	CbGpPWpGaD
Lorazepam—Rash—Prednisone—prostate cancer	4.84e-05	0.000315	CcSEcCtD
Lorazepam—Dermatitis—Prednisone—prostate cancer	4.83e-05	0.000315	CcSEcCtD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	4.83e-05	0.000674	CbGpPWpGaD
Lorazepam—Headache—Prednisone—prostate cancer	4.81e-05	0.000313	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.79e-05	0.000312	CcSEcCtD
Lorazepam—Fatigue—Doxorubicin—prostate cancer	4.79e-05	0.000312	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—ACHE—prostate cancer	4.77e-05	0.000665	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTT1—prostate cancer	4.77e-05	0.000665	CbGpPWpGaD
Lorazepam—Pain—Doxorubicin—prostate cancer	4.75e-05	0.000309	CcSEcCtD
Lorazepam—Constipation—Doxorubicin—prostate cancer	4.75e-05	0.000309	CcSEcCtD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	4.74e-05	0.000662	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC22A1—prostate cancer	4.74e-05	0.000661	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP2A6—prostate cancer	4.71e-05	0.000658	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	4.65e-05	0.000649	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ABCG5—prostate cancer	4.6e-05	0.000642	CbGpPWpGaD
Lorazepam—Estazolam—CYP3A4—prostate cancer	4.6e-05	0.00961	CrCbGaD
Lorazepam—UGT2B15—Metabolism—AKR1C3—prostate cancer	4.59e-05	0.00064	CbGpPWpGaD
Lorazepam—Feeling abnormal—Doxorubicin—prostate cancer	4.57e-05	0.000298	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—PRKACB—prostate cancer	4.56e-05	0.000636	CbGpPWpGaD
Lorazepam—Nausea—Prednisone—prostate cancer	4.56e-05	0.000297	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—CYP17A1—prostate cancer	4.51e-05	0.00063	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—GNG5—prostate cancer	4.5e-05	0.000629	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—CREBBP—prostate cancer	4.48e-05	0.000624	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—COMT—prostate cancer	4.46e-05	0.000623	CbGpPWpGaD
Lorazepam—Nitrazepam—CYP3A4—prostate cancer	4.44e-05	0.00928	CrCbGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—GNG5—prostate cancer	4.42e-05	0.000617	CbGpPWpGaD
Lorazepam—Hypersensitivity—Epirubicin—prostate cancer	4.42e-05	0.000288	CcSEcCtD
Lorazepam—Asthenia—Epirubicin—prostate cancer	4.3e-05	0.000281	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—NCOA2—prostate cancer	4.3e-05	0.0006	CbGpPWpGaD
Lorazepam—Prazepam—CYP3A4—prostate cancer	4.23e-05	0.00885	CrCbGaD
Lorazepam—GABRB3—BDNF signaling pathway—CASP3—prostate cancer	4.23e-05	0.00059	CbGpPWpGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	4.15e-05	0.000578	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—SLC5A5—prostate cancer	4.1e-05	0.000573	CbGpPWpGaD
Lorazepam—Hypersensitivity—Doxorubicin—prostate cancer	4.09e-05	0.000267	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—CTNNB1—prostate cancer	4.07e-05	0.000568	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	4.06e-05	0.000567	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP2E1—prostate cancer	4.01e-05	0.000559	CbGpPWpGaD
Lorazepam—Asthenia—Doxorubicin—prostate cancer	3.98e-05	0.00026	CcSEcCtD
Lorazepam—Dizziness—Epirubicin—prostate cancer	3.97e-05	0.000259	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—NQO1—prostate cancer	3.96e-05	0.000553	CbGpPWpGaD
Lorazepam—Flurazepam—CYP3A4—prostate cancer	3.95e-05	0.00825	CrCbGaD
Lorazepam—Triazolam—CYP3A4—prostate cancer	3.94e-05	0.00824	CrCbGaD
Lorazepam—UGT2B15—Metabolism—TH—prostate cancer	3.91e-05	0.000545	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—GNG5—prostate cancer	3.87e-05	0.000539	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP3A4—prostate cancer	3.86e-05	0.000539	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—PRKACB—prostate cancer	3.84e-05	0.000536	CbGpPWpGaD
Lorazepam—Oxazepam—CYP3A4—prostate cancer	3.82e-05	0.00799	CrCbGaD
Lorazepam—Vomiting—Epirubicin—prostate cancer	3.81e-05	0.000249	CcSEcCtD
Lorazepam—UGT2B15—Metabolism—CYP1B1—prostate cancer	3.8e-05	0.00053	CbGpPWpGaD
Lorazepam—Rash—Epirubicin—prostate cancer	3.78e-05	0.000247	CcSEcCtD
Lorazepam—Dermatitis—Epirubicin—prostate cancer	3.78e-05	0.000246	CcSEcCtD
Lorazepam—Temazepam—CYP3A4—prostate cancer	3.77e-05	0.00789	CrCbGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—PRKACB—prostate cancer	3.77e-05	0.000526	CbGpPWpGaD
Lorazepam—Headache—Epirubicin—prostate cancer	3.76e-05	0.000245	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—SRC—prostate cancer	3.68e-05	0.000514	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GGT1—prostate cancer	3.68e-05	0.000513	CbGpPWpGaD
Lorazepam—Dizziness—Doxorubicin—prostate cancer	3.67e-05	0.000239	CcSEcCtD
Lorazepam—Midazolam—CYP3A4—prostate cancer	3.66e-05	0.00765	CrCbGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—MDM2—prostate cancer	3.63e-05	0.000507	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—NCOA1—prostate cancer	3.62e-05	0.000506	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—NCOA2—prostate cancer	3.62e-05	0.000505	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP19A1—prostate cancer	3.57e-05	0.000498	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—MDM2—prostate cancer	3.57e-05	0.000497	CbGpPWpGaD
Lorazepam—Nausea—Epirubicin—prostate cancer	3.56e-05	0.000232	CcSEcCtD
Lorazepam—GABRG2—Transmembrane transport of small molecules—NCOA2—prostate cancer	3.56e-05	0.000496	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—CXCL8—prostate cancer	3.55e-05	0.000496	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—STAT3—prostate cancer	3.55e-05	0.000495	CbGpPWpGaD
Lorazepam—Vomiting—Doxorubicin—prostate cancer	3.53e-05	0.00023	CcSEcCtD
Lorazepam—Rash—Doxorubicin—prostate cancer	3.5e-05	0.000228	CcSEcCtD
Lorazepam—Dermatitis—Doxorubicin—prostate cancer	3.5e-05	0.000228	CcSEcCtD
Lorazepam—Headache—Doxorubicin—prostate cancer	3.48e-05	0.000227	CcSEcCtD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC5A5—prostate cancer	3.45e-05	0.000482	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—RXRA—prostate cancer	3.45e-05	0.000481	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—CASP3—prostate cancer	3.4e-05	0.000475	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	3.39e-05	0.000473	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—COMT—prostate cancer	3.32e-05	0.000463	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTP1—prostate cancer	3.31e-05	0.000461	CbGpPWpGaD
Lorazepam—Nausea—Doxorubicin—prostate cancer	3.3e-05	0.000215	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—PRKACB—prostate cancer	3.3e-05	0.00046	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	3.28e-05	0.000458	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ITPR1—prostate cancer	3.25e-05	0.000454	CbGpPWpGaD
Lorazepam—Diazepam—CYP3A4—prostate cancer	3.13e-05	0.00655	CrCbGaD
Lorazepam—GABRA1—Transmission across Chemical Synapses—MDM2—prostate cancer	3.12e-05	0.000435	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—NCOA2—prostate cancer	3.11e-05	0.000434	CbGpPWpGaD
Lorazepam—Clozapine—CYP3A4—prostate cancer	3.1e-05	0.00647	CrCbGaD
Lorazepam—UGT2B15—Metabolism—TYMS—prostate cancer	3.07e-05	0.000429	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—NCOA1—prostate cancer	3.05e-05	0.000426	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—EP300—prostate cancer	3.05e-05	0.000425	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTM1—prostate cancer	3.04e-05	0.000424	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—NCOA1—prostate cancer	3e-05	0.000418	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—LPL—prostate cancer	2.98e-05	0.000416	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	2.97e-05	0.000414	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—RXRA—prostate cancer	2.9e-05	0.000405	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—VEGFA—prostate cancer	2.89e-05	0.000403	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP1A1—prostate cancer	2.88e-05	0.000402	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ERCC2—prostate cancer	2.86e-05	0.000398	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—RXRA—prostate cancer	2.85e-05	0.000398	CbGpPWpGaD
Lorazepam—GABRB3—Neuronal System—MDM2—prostate cancer	2.78e-05	0.000388	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—MDM2—prostate cancer	2.73e-05	0.000381	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—MTHFR—prostate cancer	2.68e-05	0.000375	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PPARA—prostate cancer	2.63e-05	0.000367	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—NCOA1—prostate cancer	2.62e-05	0.000365	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—RXRA—prostate cancer	2.49e-05	0.000348	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CAV1—prostate cancer	2.48e-05	0.000345	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—MDM2—prostate cancer	2.39e-05	0.000333	CbGpPWpGaD
Lorazepam—GABRB3—BDNF signaling pathway—AKT1—prostate cancer	2.29e-05	0.000319	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PIK3CG—prostate cancer	2.26e-05	0.000315	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—PPARA—prostate cancer	2.22e-05	0.000309	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—PPARA—prostate cancer	2.18e-05	0.000304	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—INS—prostate cancer	2.13e-05	0.000298	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CREBBP—prostate cancer	2.09e-05	0.000292	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL6—prostate cancer	2e-05	0.000279	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PIK3CD—prostate cancer	1.98e-05	0.000277	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—PPARA—prostate cancer	1.9e-05	0.000266	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—NOS3—prostate cancer	1.87e-05	0.000261	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.76e-05	0.000246	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.73e-05	0.000241	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PIK3CB—prostate cancer	1.73e-05	0.000241	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PTGS2—prostate cancer	1.71e-05	0.000239	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.51e-05	0.000211	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PTEN—prostate cancer	1.49e-05	0.000208	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—EP300—prostate cancer	1.42e-05	0.000199	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PIK3CA—prostate cancer	1.05e-05	0.000147	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—AKT1—prostate cancer	8.61e-06	0.00012	CbGpPWpGaD
